Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia

Investigation of the Effects of Anticoagulant/Antiaggregant Use on Postoperative Bleeding Risk in Patients Operated for Bladder Tumor and Benign Prostatic Hyperplasia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05314582

Enrollment

500

Registered

2022-04-06

Start date

2022-03-10

Completion date

2023-01-10

Last updated

2023-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Transfusion Complication, Hematuria, Operative Bleeding, Retention, Urinary

Keywords

bladder cancer, benign prostatic hyperplasia, transurethral resection, hematuria

Brief summary

Patients who were using anticoagulant or antiaggregant medications for any reason and underwent transurethral resection of bladder tumor (TUR-BT) or transurethral resection of the prostate (TURP) or open prostatectomy (OP) due to BPH will be compared with those who were not using anticoagulant or antiplatelet medication. The rates of postoperative clot retention, presence of hematuria, reoperation due to hematuria, blood transfusion and re-admissions due to hematuria in the first postoperative month will be compared.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients undergoing complete endoscopic transurethral tumor resection (TUR-BT) for bladder cancer * Patients undergoing TURP due to benign prostatic hyperplasia * Patients undergoing open prostatectomy due to benign prostatic hyperplasia

Exclusion criteria

* Patients who underwent incomplete transurethral tumor resection for bladder cancer * Patient who underwent TUR biopsy for restaging with no obvious macroscopic tumoral lesion * Patients who underwent cystectomy for bladder cancer

Design outcomes

Primary

Measure	Time frame	Description
Episode of clot retention	Immediately after the surgery up to 1 month	Presence of clot retention due to hematuria after the operation which requires manuel irrigation
Requirement of blood transfusion	Immediately after the surgery up to 1 month	Gross hematuria requiring blood transfusion
Re-operation rates	Immediately after the surgery up to 1 month	Re-operation requirement for hematuria
Duration of hospitalization	Immediately after the surgery up to discharge	Duration of hospitalization
Rate of re-admission	From discharge up to one month	Rate of re-admission due to hematuria

Secondary

Measure	Time frame	Description
Postoperative hematocrit/hemoglobin levels	Immediately after the surgery up to discharge	Change in the Postoperative hematocrit/hemoglobin levels compared to the preoperative values.
Amount of irrigation volume	Immediately after the surgery up to discharge	Amount of postoperative continuous bladder irrigation volume

Countries

Turkey (Türkiye)

Outcome results